Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study

Tania Tabone, H.J. Abuhusain, Anna Nowak, Wendy Erber, K.L. Mcdonald

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug -diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. Aims: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. Method: Somatic mutation profi ling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. Results: A total of 66 mutations were detected in 35/ 44 (80%) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69%) patients. Conclusions: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes.
Original languageEnglish
Pages (from-to)550-555
JournalJournal of Clinical Pathology
Volume67
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Glioblastoma
Mutation
Therapeutics
Neoplasms
Technology
Semiconductors
Drug Combinations
Oncogenes
Biomarkers
Recurrence

Cite this

@article{a3c6a9cb00134419bc4556807e854d3d,
title = "Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study",
abstract = "Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug -diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. Aims: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. Method: Somatic mutation profi ling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. Results: A total of 66 mutations were detected in 35/ 44 (80{\%}) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69{\%}) patients. Conclusions: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes.",
author = "Tania Tabone and H.J. Abuhusain and Anna Nowak and Wendy Erber and K.L. Mcdonald",
year = "2014",
doi = "10.1136/jclinpath-2014-202173",
language = "English",
volume = "67",
pages = "550--555",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "7",

}

Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study. / Tabone, Tania; Abuhusain, H.J.; Nowak, Anna; Erber, Wendy; Mcdonald, K.L.

In: Journal of Clinical Pathology, Vol. 67, No. 7, 2014, p. 550-555.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multigene profiling to identify alternative treatment options for glioblastoma: A pilot study

AU - Tabone, Tania

AU - Abuhusain, H.J.

AU - Nowak, Anna

AU - Erber, Wendy

AU - Mcdonald, K.L.

PY - 2014

Y1 - 2014

N2 - Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug -diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. Aims: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. Method: Somatic mutation profi ling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. Results: A total of 66 mutations were detected in 35/ 44 (80%) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69%) patients. Conclusions: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes.

AB - Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug -diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. Aims: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. Method: Somatic mutation profi ling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. Results: A total of 66 mutations were detected in 35/ 44 (80%) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69%) patients. Conclusions: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes.

U2 - 10.1136/jclinpath-2014-202173

DO - 10.1136/jclinpath-2014-202173

M3 - Article

VL - 67

SP - 550

EP - 555

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 7

ER -